Literature DB >> 17952130

Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.

B E Shaw1, N H Russell.   

Abstract

The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge. In this review we summarize the outcomes of the currently available treatment modalities and discuss emerging novel approaches.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17952130     DOI： 10.1038/sj.bmt.1705888

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  7 in total

1.  Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Authors:  Marcos de Lima; Sergio Giralt; Peter F Thall; Leandro de Padua Silva; Roy B Jones; Krishna Komanduri; Thomas M Braun; Hoang Q Nguyen; Richard Champlin; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2010-07-29       Impact factor: 6.860

2.  Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation.

Authors:  Z Jedlickova; C Schmid; C Koenecke; B Hertenstein; H Baurmann; R Schwerdtfeger; J Tischer; H-J Kolb; M Schleuning
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

3.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

4.  Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.

Authors:  Masahiko Sumi; Naoaki Ichikawa; Kentaro Nasu; Ikuo Shimizu; Toshimitsu Ueki; Mayumi Ueno; Hikaru Kobayashi
Journal:  Int J Hematol       Date:  2009-11-11       Impact factor: 2.490

Review 5.  New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.

Authors:  X Chang; X Zang; C Q Xia
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

Review 6.  Relapse after allogeneic hematopoietic cell therapy.

Authors:  Marcel R M van den Brink; David L Porter; Sergio Giralt; Sydney X Lu; Robert R Jenq; Alan Hanash; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-24       Impact factor: 5.742

7.  Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission.

Authors:  Rada M Grubovikj; Asif Alavi; Ahrin Koppel; Mary Territo; Gary J Schiller
Journal:  Cancers (Basel)       Date:  2012-06-20       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.